COMPARISON BETWEEN BROMOCRIPTINE AND SELEGILINE IN TREATMENT OF PARKINSON*S DISEASE

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

AHMADI AHANGAR A.J.; SADRAIE A.R.; ASHRAF VAGHEFI S.B.; RAMESANI M.S.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: DARU Journal of Pharmaceutical Sciences Year:2005 | Volume:13 | Issue:1 Page(s): 23-27

Download Full-Text

View:

454

Download:

161

Cites:

Information Journal Paper

Title

COMPARISON BETWEEN BROMOCRIPTINE AND SELEGILINE IN TREATMENT OF PARKINSON*S DISEASE

Author(s)

AHMADI AHANGAR A.J. | SADRAIE A.R. | ASHRAF VAGHEFI S.B. | RAMESANI M.S. | Issue Writer Certificate

Keywords

PARKINSON*S DISEASE

DYSKINESIA

LEVODOPA

SELEGILINE

BROMOCRIPTINE.

Abstract

Parkinson*s disease is a common degenerative disease that causes rigidity, bradykinesia and rest tremor in patients. Available treatments include LEVODOPA (the major drug) and other supplementary drugs (bromocriptine or selegiline) which can reduce such disabilities, but because of the necessity of their uses for a long term treatment, many side effects are being expected. Thus, due to lack of sufficient reports about efficacy and side effects of such supplementary drugs, this experimental study was carried out.Seventy seven patients (50 men and 27 women) with the average age of 68±8.42 years were divided into three groups. In group A, LEVODOPA and trihexyphenidyl (Artan®) were administered to 18 patients. In group B, SELEGILINE (Deprenyl®) was used as a supplementary and was administered with LEVODOPA and trihexyphenidyl for 25 patients. In group C, BROMOCRIPTINE.was used in place of selegiline, for 34 patients.In a three year period, the patients were followed up, in conformity with UPDRS (Unified Parkinson*s Disease Rate Scale). In this experimental study, group C showed better physical activities in comparison with group A and group B, in spite of having better conditions at the first year showed totally little differences in comparison with group A. With a view to side effect particularly dyskinesia; there was little side effect in group C. On the basis of results of this investigation it appears that BROMOCRIPTINE.as a supplementary drug in comarison to SELEGILINE has fewer side effects.

Cites

No record.

References

Cite

APA: Copy

AHMADI AHANGAR, A.J., SADRAIE, A.R., ASHRAF VAGHEFI, S.B., & RAMESANI, M.S.. (2005). COMPARISON BETWEEN BROMOCRIPTINE AND SELEGILINE IN TREATMENT OF PARKINSON*S DISEASE. DARU JOURNAL OF PHARMACEUTICAL SCIENCE, 13(1), 23-27. SID. https://sid.ir/paper/275231/en

Vancouver: Copy

AHMADI AHANGAR A.J., SADRAIE A.R., ASHRAF VAGHEFI S.B., RAMESANI M.S.. COMPARISON BETWEEN BROMOCRIPTINE AND SELEGILINE IN TREATMENT OF PARKINSON*S DISEASE. DARU JOURNAL OF PHARMACEUTICAL SCIENCE[Internet]. 2005;13(1):23-27. Available from: https://sid.ir/paper/275231/en

IEEE: Copy

A.J. AHMADI AHANGAR, A.R. SADRAIE, S.B. ASHRAF VAGHEFI, and M.S. RAMESANI, “COMPARISON BETWEEN BROMOCRIPTINE AND SELEGILINE IN TREATMENT OF PARKINSON*S DISEASE,” DARU JOURNAL OF PHARMACEUTICAL SCIENCE, vol. 13, no. 1, pp. 23–27, 2005, [Online]. Available: https://sid.ir/paper/275231/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops